This study was designed to evaluate the safety and tolerability of @entity901 combined with weekly boluses of @entity1487 ( @entity1487 ) and low doses of @entity4181 (LV) and to determine objective response, progression-free survival, and overall survival of @entity1 with previously untreated advanced @entity14 . Seventy-nine @entity1 enrolled in an observational, multicenter, prospective, open-label phase II study received intravenous (I.V.) infusions of @entity901 85 mg/m2 over the course of 2 hours on days 1 and 14 and LV 20 mg/m2 over the course of 2 hours and @entity1487 500 mg/m2 as a bolus on days 1, 7, and 14 every 4 weeks until disease progression or unacceptable @entity137 occurred. Seventy-nine @entity1 were evaluable for safety, and data from 70 @entity1 were used for efficacy analysis. The objective response rate was 51.4%. Complete responses occurred in 7 @entity1 (10%), and partial responses occurred in 29 @entity1 (41.4%). Disease control, defined as response or stable disease, was obtained in 56 of 70 @entity1 (80%). The median duration of response was 8.34 weeks (range, 7.3-11.5 weeks). The median time to progression was 7.13 months (range, 6.28-7.72 months), and median overall survival time was 15 months (range, 12.32-18.37 months). Acute dose-limiting @entity137 were grade 3/4 @entity294 and @entity1398 , which occurred in 10.5% and 3.9% of @entity1 , respectively. Among the 70 @entity1 who experienced @entity137 , it was estimated that only 1.3% had grade 3 symptoms. Preliminary data showed that the regimen is at least as active as other regimens combining @entity901 and infusional schedules of @entity1487 and might be more convenient for @entity1 because it avoids the need for I.V. catheter implantation.

Activity and safety of @entity901 with weekly @entity1487 bolus and low-dose XXXX as first-line treatment for advanced @entity14 .

@entity901 :: ('MESH:C030110', 'Chemical') :: ['oxaliplatin'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity4181 :: ('MESH:D002955', 'Chemical') :: ['leucovorin'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities', 'neurosensory toxicity'] @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-FU', '5-fluorouracil']
@entity4181 :: (MESH:D002955,Chemical) :: ['leucovorin']
